























![]()
Q1: 2026-05-11 Earnings Summary
EPS of -$0.25 beats by $0.02
|
Revenue of
$12.31M
(-69.02% Y/Y)
misses by $1.91M
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call May 11, 2026 5:00 PM EDT
Company Participants
Carrie Graham - Vice President of Investor Relations & Advocacy
Dennis Lanfear - Chairman, President & CEO
Rosh Dias - Chief Medical Officer
Theresa Lavallee - Chief Development Officer & Chairman of Scientific Advisory Board
Sameer Goregaoker - Chief Commercial Officer
Bryan McMichael - Chief Financial Officer
Conference Call Participants
Jay Olson - Oppenheimer & Co. Inc., Research Division
Paul Jeng - Guggenheim Securities, LLC, Research Division
Lut Ming Cheng - JPMorgan Chase & Co, Research Division
Nick Quartapella - Robert W. Baird & Co. Incorporated, Research Division
Michael Nedelcovych - TD Cowen, Research Division
Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q1 2026 Coherus Oncology, Inc. Earnings Conference Call.
[Operator Instructions]
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead.
Carrie Graham
Vice President of Investor Relations & Advocacy
Thank you, Heidi. Good afternoon, and welcome to Coherus Oncology's First Quarter 2026 Earnings Conference Call. Joining me today to discuss our results are Denny Lanfear, Chief Executive Officer of Coherus; Dr. Rosh Dias, Chief Medical Officer; Dr. Theresa Lavallee, Chief Scientific and Development Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer.
Before we get started, I would like to remind you that today's call includes forward-looking statements regarding Coherus' current expectations about future events. Actual results may vary significantly, and we undertake no duty to update or revise any forward-looking statements. Please see the press release that we issued today and our quarterly report on Form 10-Q for more information on risks and uncertainties.
And now I'll turn the call over to Denny.
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。